Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Indian pharma giant Cipla released its Q4 FY 25 result, wherein it posted a healthy year-on-year growth of 30% in net profit ...

Cipla , India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Cipla on May 13 reported a 30 percent on-year jump in net profit to Rs 1,222 crore for the fourth quarter of the financial ...

Cipla's CEO Umang Vohra asserts that the US mandate for lowering prescription drug costs will not affect Indian generic ...

Cipla MD Umang Vohra assured that the US government's directive to lower prescription drug costs will not impact Indian ...

The board has fixed June 27 as the record date for the purpose of payment of final dividend, as per an exchange filing.